← Leaderboards
Dennis O Adeegbe
H. Lee Moffitt Cancer Ctr & Res Inst
$970,941
Attributed
$970,941
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $423.5K · FY2018–21$500K$375K$250K$125K$0
'18
'19
'20
'21
Funding mix
By agency
NIH$970,941 · 2
By mechanism
K22$547,455 · 1
R21$423,486 · 1
Top collaborators
No co-investigators on record.
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Nagi B Kumar$8,902,562
- Jong Y Park$3,295,954
- Elsa R Flores$12,484,914
- Laura Madeline Heiser$5,676,081
- Uwe Rix$4,190,386
Others in their field
Other Emerging Leaders on “Phenotype”
- Leonard Freedman · Leidos Biomedical Research, Inc.$68,463,085
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Lynn Briscoe · Leidos Biomedical Research, Inc.$28,580,688
- Evan Z Macosko · Broad Institute, Inc.$28,218,682
- Badri N Vardarajan · University Of Miami School Of Medicine$23,982,327
Research focus
PhenotypeTumor-Infiltrating Immune CellsImmunotherapeutic AgentPharmaceutical PreparationsShapesTumorEpigenetic ProcessImmunoregulationExhibitsMalignant Neoplasm Of LungRecruitResponseCancer EtiologyT-LymphocyteCancer PatientBaseImmuneCellsCessation Of LifeClinical ApplicationInhibitor/AntagonistInsightPropertyTumor Microenvironment
Grant awards (4)
Dissecting the immunological mechanisms associated with prostate cancer progression in African-American men and exploring epigenetics-based immune modulation for therapy$423,486
R21 · FY2021 · CA · contact PI
Investigating mechanistic underpinnings and therapeutic potential of selective histone deacetylase and bromodomain inhibition for the treatment of non-small cell lung cancer$182,485
K22 · FY2020 · CA · contact PI
Investigating mechanistic underpinnings and therapeutic potential of selective histone deacetylase and bromodomain inhibition for the treatment of non-small cell lung cancer$182,485
K22 · FY2019 · CA · contact PI
Investigating mechanistic underpinnings and therapeutic potential of selective histone deacetylase and bromodomain inhibition for the treatment of non-small cell lung cancer$182,485
K22 · FY2018 · CA · contact PI